Brainstorm Cell Ther (BCLI) 4.29 $BCLI Premarket Gainers

New Post Public Reply Private Reply Replies (0) Message Board

Apr 23, 2015 at 1:35 AM

Brainstorm Cell Ther (BCLI) 4.29 $BCLI

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:22AM CDT

HOG: 56.23 (+0.51), TNXP: 6.73 (+0.21), ALNY: 118.00 (-2.70), LRE: 8.43 (+0.08), LRCX: 78.36 (+0.52), MYL: 72.40 (-1.67), NVGN: 7.40 (-0.30), BIOC: 3.15 (+0.02), NBG: 1.19 (+0.12), VLTC: 15.14 (-1.04), FTNT: 38.07 (-0.01), BCLI: 4.29 (-0.09), SANM: 21.09 (+0.40)

BrainStorm's NurOwn shows encouraging results in ALS; shares up 11% premarket
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:16AM CDT

BCLI: 4.29 (-0.09)

BrainStorm's NurOwn® Demonstrates a Statistically Significant Effect in ALS Patients
PR Newswire - Tue Apr 21, 5:55AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) at a poster session today at the American Academy of Neurology annual meeting, taking place in Washington D.C. In addition to previously disclosed topline results, further data and analyses are being presented for the first time today.
BCLI: 4.29 (-0.09)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT

SPPR: 2.55 (-0.16), FNRG: 3.11 (-0.86), BIOC: 3.15 (+0.02), NVGN: 7.40 (-0.30), AMPE: 2.89 (+0.20), TRIL: 20.67 (-2.53), CZR: 9.68 (-0.24), TLOG: 4.70 (-0.21), BCLI: 4.29 (-0.09), STDY: 10.10 (+0.11), GENE: 4.88 (-0.05), FARO: 44.64 (-0.93), ICON: 27.06 (+0.45), XXII: 1.50 (+0.04), XBIT: 27.55 (+0.18), UEC: 2.12 (+0.29), COOL: 1.40 (-0.21), CALA: 12.93 (-1.06), WPCS: 3.71 (-0.17), VIMC: 13.42 (+1.31)

Next Week In Biotech: Amgen, AbbVie, Biogen Earnings, UniQure CHMP, AAN Meeting
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
ABT: 48.35 (+1.23), BIIB: 423.57 (+1.46), NEO: 4.84 (-0.03), SGMO: 14.37 (-0.03), IMGN: 9.96 (+0.01), AMGN: 169.10 (+0.64), ILMN: 190.04 (-9.27), SVA: 5.06 (+0.10), BCLI: 4.29 (-0.09), ISRG: 516.93 (-29.80), BABY: 41.64 (+1.71), QURE: 26.15 (-1.44), NURO: 1.32 (-0.02), ABAX: 63.25 (-0.09), GWPH: 113.04 (-0.05), ALXN: 188.19 (+1.41), ABBV: 64.52 (+0.91), AMAG: 57.68 (+0.47), CAT: 84.87 (+0.95), MAA: 76.57 (+1.00), NVS: 103.45 (-0.62)

Nasdaq stocks posting largest percentage increases
AP - Tue Apr 14, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
HTBX: 7.71 (-0.64), DOVR: 8.42 (-0.02), STCK: 18.52 (-0.02), CLVS: 85.04 (-1.36), ORMP: 7.25 (-0.10), BIND: 7.01 (-0.30), EGRX: 60.53 (+1.22), VLTC: 15.14 (-1.04), BCLI: 4.29 (-0.09), REPH: 10.71 (-0.78)

Brainstorm Cell Therapeutics (BCLI) Stock Gains Today on Potentially Positive Phase 2a Results
at The Street - Tue Apr 14, 9:48AM CDT
Brainstorm Cell Therapeutics (BCLI) shares are gaining as the company prepares to release a report on its phase 2a ALS treatment study.
BCLI: 4.29 (-0.09)

Brainstorm up in anticipation of NurOwn ALS results
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 8:52AM CDT

BCLI: 4.29 (-0.09)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 8:12AM CDT

NSC: 104.97 (+2.56), ARWR: 6.88 (+0.14), GWPH: 113.04 (-0.05), ALU: 4.12 (+0.09), NVGN: 7.40 (-0.30), BLDR: 13.00 (-0.09), BCLI: 4.29 (-0.09), EGY: 2.29 (-0.07), SZYM: 3.71 (-0.06)

BrainStorm Cell Therapeutics to Present Positive NurOwn® Phase 2a Clinical Data at American Academy of Neurology Annual Meeting
PR Newswire - Tue Apr 14, 6:00AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Academy of Neurology annual meeting, taking place in Washington D.C. from April 18 to 25, 2015.
BCLI: 4.29 (-0.09)

Brainstorm Rallies On Endorsement Of Competitor's Drug
Jason Napodano, CFA - at Seeking Alpha - Mon Apr 13, 10:54AM CDT

BCLI: 4.29 (-0.09)

Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.80 (-0.03), NBS: 2.88 (+0.06), OSIR: 16.35 (-0.10), BCLI: 4.29 (-0.09), MDVN: 128.88 (+0.29), INO: 10.39 (-0.09), CYTX: 0.96 (-0.09), STEM: 0.82 (-0.06), JUNO: 55.72 (-0.68), ATHX: 1.34 (+0.01), CUR: 1.96 (-0.04), BLUE: 136.49 (+1.22), VRTX: 132.85 (+0.65), AMGN: 169.10 (+0.64), KERX: 11.52 (-0.15), OMER: 24.41 (-0.15), KITE: 57.56 (-1.43), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), TEVA: 63.01 (-1.15)

Why You Should Own Brainstorm Cell Therapeutics
Jason Napodano, CFA - at Seeking Alpha - Sat Mar 28, 7:34AM CDT

BCLI: 4.29 (-0.09)

BrainStorm Cell Therapeutics' (BCLI) CEO Tony Fiorino on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 26, 9:48AM CDT

BCLI: 4.29 (-0.09)

BrainStorm Cell Therapeutics Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 7:43AM CDT

BCLI: 4.29 (-0.09)

BrainStorm Cell Therapeutics misses by $0.03
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 7:29AM CDT

BCLI: 4.29 (-0.09)

BrainStorm Announces Financial Results for 2014 and Provides Business Update
PR Newswire - Thu Mar 26, 7:26AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.
BCLI: 4.29 (-0.09)

4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Tue Mar 24, 1:13PM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
ECYT: 6.37 (unch), SNSS: 2.57 (-0.11), BCLI: 4.29 (-0.09), XOMA: 3.63 (-0.04)

BrainStorm Cell Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on Thursday, March 26
PR Newswire - Thu Mar 19, 3:15PM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report fourth quarter and full year 2014 financial results on Thursday, March 26, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the financial results and answer questions.
BCLI: 4.29 (-0.09)

BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New York
PR Newswire - Wed Mar 18, 8:16AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that CEO Tony Fiorino, MD, PhD, will present at the 3rd Annual Regen Med Investor Day to be held Wednesday, March 25, 2015 in New York City.
BCLI: 4.29 (-0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Atlas Unveils Luxurious Owner's Suites on New Yacht

Set Sail into Opulent Luxury The upcoming debut of the Atlas Adventurer yacht promises to redefine luxury at sea with its exclusive Owner's Suites. Yeah, you heard that right—these aren't your average cabins. Atlas Ocean Voyages is shooting for the stars here, rolling out the yacht's crown jewel of accommodations that's got everyone buzzing. Nestled on Deck 6, above the...

Mixed Wage Growth: Gains for Some, Challenges Persist

A Closer Look at Q3 Earnings I tell you, these numbers from the Ludwig Institute make for a pretty mixed bag. Sure, we got a slight nudge upwards in those median weekly earnings for the third quarter, like from $1,035 to $1,041. It’s a pinch of positive news, but hang on a sec before you start celebrating. The reality ain't shifting for a lot of folks, especially if...

LFG Charts New Path with Expanded Franchise Lineup

A Unique Approach to Franchise Expansion LFG, or Limitless Franchise Growth if you prefer function over flair, is taking its expansion game to a different level. Based out of Scottsdale, these savvy folks have just beefed up their portfolio to nine diverse brand partners. You’d think they’re all about boosting numbers, right? But nah, they're so picky you'd think...

TransPerfect Launches College Bowl Game in Puerto Rico

Puerto Rico Welcomes College Football with Open Arms Imagine kicking towards the goalposts while the ocean breeze kisses your face—yep, that's what's happening in Puerto Rico this December. TransPerfect, a heavyweight in language and tech solutions, is rolling out the red carpet for the inaugural TransPerfect San Juan Bowl, and it’s not just a game. It’s a bold step...

Low GWP Refrigerants: Potential $13B Market by 2031

Refrigerants: They're Hot in More Ways Than One Who would've thought refrigerants could be such a big deal? But here we are. The low global warming potential (GWP) refrigerants market is heating up, projected to jump from $8.17 billion in 2026 to a whopping $13.06 billion by 2031. That's a solid 9.8% CAGR if you're keeping score. The drivers? Well, we’ve got...

Tucows Preps for Q3 Financial Reveal on November 5th

A New Financial Landscape Unfolds Ah, another earnings season looms on the horizon, and Tucows Inc. has flagged November 5, 2026, as the day the curtain rises for its third-quarter financial results. Right after the market closes at exactly 5:05 p.m. ET, Tucows plans to dish out its numbers, giving investors and analysts the meat and potatoes they crave by way of a news...

Haystack Expands MCP to Boost AI Intranet Workflow

Bridging the Intranet and AI: A Game Changer? You ever feel like your company's intranet is a black hole, swallowing all the information you need before spitting it back out in a chaos of outdated pages and broken links? Well, Haystack aims to clear that fog with their Model Context Protocol (MCP) server. And starting October 26, the game takes a leap forward. Now, not...

D-Wave Investors Face Pressure Ahead of December 15

Investors Eye December 15 Deadline Nothing like a looming deadline to stir up some anxiety among investors, and that's exactly what's going down at D-Wave Quantum Inc. right now. We're talking about the class action lawsuit spearheaded by the firm Robbins Geller Rudman & Dowd LLP. They've sent out a call to arms for investors who suffered significant losses from February...

Revolutionizing Textiles: Touchscreen Garments Emerge

Picture a world where your shirt does more than just cover your back. Bingo, folks—smart textiles have taken center stage with groundbreaking technology that melds touchscreens with fabric, and the brains behind it hail from the National University of Singapore (NUS). It's not just about slapping a few LEDs onto a vest. We're talking about clothing that can display...

California Waste Solutions: Investing in Vietnam's Future

Some folks see trash. David Duong sees hope—and dollar signs. This man ain't just talking trash collection; he's flipping waste into opportunity and, more importantly, into core community building in Vietnam. Over at Vietnam Waste Solutions, a subsidiary of California Waste Solutions, they're blending environmental breakthroughs with good old-fashioned community values....